• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Protalix BioTherapeutics Inc. (DE) (Amendment)

    1/2/24 6:36:07 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PLX alert in real time by email
    SC 13G/A 1 zk2430712.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
    Under the Securities Exchange Act of 1934

    Protalix BioTherapeutics, Inc.

    (Name of Issuer)
     
    Common Stock, Par Value $0.001 per Share

    (Title of Class of Securities)
     
    74365A309
    (CUSIP Number)

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☐ Rule 13d-1(b)
     
    ☒  Rule 13d-1(c)
     
    ☐ Rule 13d-1(d)
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     
    CUSIP
    NO.

    74365A309
       
    1
    NAMES OF REPORTING PERSONS
     
     
    Angels Investments in Hi Tech Ltd

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☒
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     

    Israel
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
     

    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     

    2,208,913 shares*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     

    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     

    2,208,913 shares*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     

    2,208,913 shares*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     

    2.9%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     

    CO
     
     
     
     

    *          Consists of 237,012 shares of Common Stock of the Issuer and 1,971,901 shares of Common Stock of the Issuer that the Reporting Person has the right to acquire pursuant to warrants that are exercisable within 60 days of December 31, 2023.

    Page 2 of 7 Pages


    CUSIP
    NO.

    74365A309
       
    1
    NAMES OF REPORTING PERSONS
     
     
    Marius Nacht

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☒
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     

    Israel
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
     

    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     

    2,208,913 shares*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     

    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     

    2,208,913 shares*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     

    2,208,913 shares*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     

    2.9%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     

    IN
     
     
     
     

    *          Consists of 237,012 shares of Common Stock of the Issuer and 1,971,901 shares of Common Stock of the Issuer that the Reporting Person has the right to acquire pursuant to warrants that are exercisable within 60 days of December 31, 2023.

    Page 3 of 7 Pages

    Item 1(a)
    Name of Issuer

    Protalix BioTherapeutics, Inc. (the “Issuer”).

    Item 1(b)
    Address of Issuer’s Principal Executive Offices

    2 Snunit Street, Science Park, POB 455, Carmiel 2161401, Israel
     
    Item 2(a)-(b)    Name of Person Filing; Address of Principal Business Office or, if none, Residence
     

    1.
    Angels Investments in Hi Tech Ltd. (“Angels”) c/o Marius Nacht, 42 Brandeis St. Tel Aviv 6200157, Israel


    2.
    Marius Nacht, 42 Brandeis St. Tel Aviv 6200157, Israel


    The foregoing persons are hereinafter collectively referred to as the “Reporting Persons”.
             
    Item 2(c)
    Citizenship

    Angels is an Israeli company; and Marius Nacht is an Israeli citizen. 
             
    Item 2(d)
    Title of Class of Securities

    Common Stock, par value $0.001 per share
             
    Item 2(e)
    CUSIP Number

    74365A309

    Item 3
    If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

    Not applicable.

    Item 4
    Ownership

    Angels Investments in Hi Tech Ltd.


    (a)
    Amount beneficially owned: 2,208,913 shares of Common Stock.

    The number of shares of Common Stock set forth above consists of 237,012 shares of Common Stock and 1,971,901 shares of Common Stock of the Issuer that the Reporting Person has the right to acquire pursuant to warrants that are exercisable within 60 days of December 31, 2023

    All share percentage calculation are based on (i) 72,952,124 shares of Common Stock outstanding as of November 1, 2023, as reported by the Issuer to the SEC on Form 10-Q on November 6, 2023 and (ii) 1,971,901  shares of Common Stock of the Issuer that the Reporting Person has the right to acquire pursuant to warrants that are exercisable within 60 days of December 31, 2023, which are treated as issued and outstanding solely for the purpose of computing the percentage ownership of the Reporting Person pursuant to Rule 13d-3(d)(1)(i) under the Act.


    (b)
    Percent of Class: 2.9%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 2,208,913 shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 2,208,913 shares of Common Stock

    Page 4 of 7 Pages

    Marius Nacht


    (a)
    Amount beneficially owned: 2,208,913 shares of Common Stock. Marius Nacht is the sole shareholder and director of Angels. By reason of Mr. Nacht‘s control over Angels,  By virtue of such relationship, Marius Nacht may be deemed to have shared voting and investment power with respect to the shares of Common Stock of the Issuer held by Angels.

    The number of shares of Common Stock set forth above consists of 237,012 shares of Common Stock and 1,971,901 shares of Common Stock of the Issuer that the Reporting Person has the right to acquire pursuant to warrants that are exercisable within 60 days of December 31, 2023

    All share percentage calculation are based on (i) 72,952,124 shares of Common Stock outstanding as of November 1, 2023, as reported by the Issuer to the SEC on Form 10-Q on November 6, 2023 and (ii) 1,971,901  shares of Common Stock of the Issuer that the Reporting Person has the right to acquire pursuant to warrants that are exercisable within 60 days of December 31, 2023, which are treated as issued and outstanding solely for the purpose of computing the percentage ownership of the Reporting Person pursuant to Rule 13d-3(d)(1)(i) under the Act.


    (b)
    Percent of Class: 2.9%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 2,208,913 shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 2,208,913 shares of Common Stock

    Item 5
    Ownership of Five Percent or Less of a Class

    If this statement is being filed is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

    Item 6
    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.
     
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

    Not applicable.
     
    Item 8
    Identification and Classification of Members of the Group

    Incorporated by reference to Items 2 and 4 of this Schedule 13G.
     
    Item 9
    Notice of Dissolution of Group

    Not applicable.

    Item 10
    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Page 5 of 7 Pages


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Dated: January 2, 2024
     

    ANGELS INVESTMENTS IN HI TECH LTD.

    By: /s/ Marius Nacht
           Name: Marius Nacht
           Title:   Sole Shareholder

    MARIUS NACHT

    By: /s/ Marius Nacht

    Page 6 of 6 Pages

    Get the next $PLX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PLX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLX
    SEC Filings

    View All

    Amendment: SEC Form S-3/A filed by Protalix BioTherapeutics Inc. (DE)

    S-3/A - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

    8/14/25 7:10:42 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Protalix BioTherapeutics Inc. (DE)

    10-Q - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

    8/14/25 7:05:53 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

    8/14/25 6:58:16 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

    Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, Aug. 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended June 30, 2025, and provided a business and clinical update. "We experienced a 50% increase in revenues from selling goods in the first half of 2025 compared to the same period in 2024," said Dror Bashan, Protalix's President and Chief Executive Officer. "The increase i

    8/14/25 6:50:00 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

    Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, Aug. 7, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended June 30, 2025 and provide a business and clinical update on August 14, 2025. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details: Date:  Thursday

    8/7/25 12:53:00 PM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

    CARMIEL, Israel, July 21, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the appointment of Gilad Mamlok to serve as the Company's new Senior Vice President and Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin. To ensure a seamless transition, Mr. Mamlok has joined the company and is working alongside Mr. Rubin. After his tenure as Chief Financial Officer ends, Mr. Rubin will continue to be available to the Company as ne

    7/21/25 6:50:00 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Protalix BioTherapeutics with a new price target

    HC Wainwright & Co. reiterated coverage of Protalix BioTherapeutics with a rating of Buy and set a new price target of $7.00 from $11.00 previously

    5/3/21 7:36:38 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schwartz Aharon bought $205,884 worth of shares (129,000 units at $1.60), increasing direct ownership by 74% to 303,000 units (SEC Form 4)

    4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

    8/12/25 4:30:07 PM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Elze Christian

    3 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

    7/3/25 4:30:17 PM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Sr. VP and CFO Rubin Eyal was granted 90,909 shares (SEC Form 4)

    4/A - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

    11/5/24 5:00:15 PM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schwartz Aharon bought $205,884 worth of shares (129,000 units at $1.60), increasing direct ownership by 74% to 303,000 units (SEC Form 4)

    4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

    8/12/25 4:30:07 PM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bashan Dror bought $90,484 worth of shares (64,516 units at $1.40), increasing direct ownership by 95% to 132,516 units (SEC Form 4)

    4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

    10/20/23 6:50:07 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLX
    Leadership Updates

    Live Leadership Updates

    View All

    Levicept Appoints Eliot Forster as CEO

    Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

    11/30/23 4:00:00 AM ET
    $IMCR
    $IMTX
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

    Appointment effective as of September 14, 2023;Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel, Sept. 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that the Company's Board of Directors has appointed Eliot Richard Forster, Ph.D. to serve on the Board of Directors as its Chairman, effective as of September 14, 2023. In

    9/12/23 6:50:00 AM ET
    $IMTX
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors

    CARMIEL, Israel, June 30, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), announced today that the Company's Board of Directors has appointed Shmuel "Muli" Ben Zvi, Ph.D. to serve on the Company's Board of Directors. In addition to Dr. Ben Zvi's appointment as an independent director, he was also appointed to serve on the Company's Audit Committee and Compensation Committee. "We are excited to have Muli join our Board of Directors," commented Zeev Bronfeld, Chairman of Protalix's Board of Directors. "He brings extensive financial and economic knowle

    6/30/22 4:30:00 PM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLX
    Financials

    Live finance-specific insights

    View All

    Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

    Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, Aug. 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended June 30, 2025, and provided a business and clinical update. "We experienced a 50% increase in revenues from selling goods in the first half of 2025 compared to the same period in 2024," said Dror Bashan, Protalix's President and Chief Executive Officer. "The increase i

    8/14/25 6:50:00 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

    Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, Aug. 7, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended June 30, 2025 and provide a business and clinical update on August 14, 2025. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details: Date:  Thursday

    8/7/25 12:53:00 PM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

    Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update. "We had another solid quarter, with an increase in revenues from selling goods compared to the prior year quarter," said Dror Bashan, Protalix's President and Chief Executive Officer. "Given the promising resul

    5/9/25 6:50:00 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Protalix BioTherapeutics Inc. (DE)

    SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)

    10/25/24 4:23:48 PM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Protalix BioTherapeutics Inc. (DE) (Amendment)

    SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)

    1/2/24 6:36:07 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Protalix BioTherapeutics Inc. (DE) (Amendment)

    SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)

    1/3/23 6:01:32 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care